Press Releases

Press Releases

or

May 20, 2020
CAMBRIDGE, Mass. and BEIJING, China , May 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced
May 11, 2020
CAMBRIDGE, Mass. and BEIJING, China , May 11, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported
April 13, 2020
BEIJING, China , and CAMBRIDGE, Mass. , April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today
March 25, 2020
- NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company - As the marketing agent for ABRAXANE in China , BeiGene is working with BMS to restore supply in China BEIJING, China , and CAMBRIDGE, Mass.